Select Page

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

Jan 12, 2021 | Press Releases | 0 comments

Alexander Sonneborn

NEW YORK, January 12, 2021 – EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based off of an ab initio designed antibody.

EVQLV’s 100 sample validation run was designed to validate the company’s claim that they could ab initio design an antibody by computer (without prior templates) that would hit a target epitope. This time around, EVQLV wants to know, given an antibody that binds to a target epitope, how many lead-ready antibodies they can generate that hit the target within a predefined affinity range. EVQLV’s goal is to create a large range of antibodies with limited developability risks and binding affinities. EVQLV’s laboratory collaborator will use their proprietary technology to compile the one million submitted sequences into a sub-library.

Results are expected by Q3 2021.


EVQLV, Manhattan BioSolutions Announce UB CAT Grant Award

University at Buffalo Center for Advanced Technology in Big Data and Health Sciences New York City, New York Jun 29, 2021 (  - EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, and...

NY Bio-Computation Startup EVQLV Closes Financing Round

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...

Fully Automated Rabbit Humanization Project Initiated w/ U Buffalo

NEW YORK, December 16, 2020 -- EVQLV is eagerly anticipating the results from the second phase of their University at Buffalo rabbit-humanization collaboration. Starting with rabbit monoclonal antibodies, EVQLV is attempting to validate its fully-automated...

EVQLV Accepted to Prestigious Techstars Boston Accelerator

NEW YORK, November 18, 2020 -- EVQLV, a New York company that uses AI to accelerate the development of antibodies, will be one of 10 startups in the new class of the Techstars Boston program. This year’s program will be 100% virtual and, for the first time, will...